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Transforming growth factor-b1 (TGF-b1) potently induces the epithelial-mesenchymal transition
(EMT) during tumoral progression. Although Sky-interacting protein (SKIP) regulates TGF-b1-
induced Smad activation, its role in the induction of cell malignance remains uncertain. We found
that TGF-b1 increases SKIP expression in PDV cells. In cells stably transfected with SKIP antisense,
AS-S, Smad3 activation decreased, along with an inhibition of TGF-b1-induced EMT, and the cells
were sensitized to the TGF-b1-dependent inhibition of proliferation. Also, AS-S cells showed a
weaker migration and invasion response. Moreover, TGF-b1-induced urokinase-type plasminogen
activator expression was inhibited, concomitantly with a TGF-b1-independent increment of the plas-
minogen-activator inhibitor-1 expression. Thus, these results suggest that SKIP is required for EMT
and invasiveness induced by TGF-b1 in transformed cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction with VDR and v-Ski proto-oncogene using yeast 2-hybrid screeningThe Transforming growth factor-b1 (TGF-b1) super-family of
factors is implicated in the regulation of cell proliferation, differen-
tiation, apoptosis, migration, and epithelial-mesenchymal transi-
tion (EMT). EMT is important during embryonic development,
and also has a role in malignancy as it favours tumour cell invasion
and metástasis [1,2]. TGF-b1 at early stages of carcinogenesis
inhibits tumorigenesis by acting as a tumour suppressor. However,
in later steps, TGF-b1 stimulates malignant progression in tumour
cells that have attenuated or lost the TGF-b1 growth inhibitory re-
sponse [3,4]. TGF-b1 binds to the functional complex of TGF-b fam-
ily of cell surface receptors and activates Smad2,3 and Smad-
independent signals such as ERK1,2 MAPK [5].
As recently reported, Sky-interacting protein (SKIP) interacts
with Smad2,3 to augment the TGF-b1-dependent transcription,
suggesting that SKIP plays a role in the regulation of cell growth
and differentiation through the TGF-b pathway [6]. SKIP was orig-
inally isolated as a putative co activator protein which interactschemical Societies. Published by E
r-b1; EMT, epithelial-mesen-
AI-1, plasminogen activator
tivator
ental Research, Institute for
tica 4, P.O. Box 102, 11129
ibanez).strategies [7,8]. SKIP is a well-conserved transcriptional adaptor
protein which, depending on the cellular context, functions to re-
cruit either activation or repression complexes to mediate multiple
signaling pathways involved in the control of cell proliferation and
differentiation [9]. Potential function of the SKIP–Ski complex is to
overcome the growth-suppressive activities of retinoblastoma pro-
tein [10]. In addition, SKIP is upregulated by estradiol-17beta and
promotes anchorage-independent growth in ovarian carcinoma
cells [11]. However, its precise role in stimulation of tumorigenesis
by TGF-b1 is poorly understood.
In this research, it was analyzed whether SKIP regulates TGF-
b1-enhanced EMT and invasiveness of transformed cells. We found
that the depletion of SKIP by antisense strategy blocks the induc-
tion of EMT and cell migration, altogether with the inhibition of
urokinase-type plasminogen activator (uPA) system by TGF-b1
and enhances plasminogen activator inhibitor type-1 (PAI-1)
expression. These results allow us to suggest a critical role for SKIP
in the enhancement of malignance by TGF-b1 in transformed cells.
2. Materials and methods
2.1. Plasmids and antibodies
Mouse pREP4 (Antisense mouse SKIP) was kindly provided by
Dr. D. Haywars, John Hopkins University School of Medicine,lsevier B.V. All rights reserved.
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provided by Dr. C. Bernabeu (CIB, Spain). CAGAC-luc reporter was
kindly provided by Dr. P. Ten Dijke (LUMC, The Netherlands).
pGL3-E2F reporter with 4 E2F sites was kindly provided by Dr.
Jianrong Lu, University of Florida College of Medicine (USA).
The SKIP rabbit antibody (C-15) was purchased from Santa Cruz
Biotechnology, CA. Anti-HA, anti-E-cadherin, anti-ﬁbronectin, anti-
vimentin, anti-a-tubulin and secondary antibodies-coupled with
HPO or FITC were from Sigma (St. Louis, MO). Anti ZO-1 antibody
was from Cell Signalling Technology Inc. (Danvers, MA). Anti-
p-Smad3 and anti-Smad2/3 antibodies were purchased from
Calbiochem (Darmstadt, Germany).2.2. Cell culture and transfection procedures
PDV cells, kindly provided by Dr. M. Quintanilla, IIB-CSIC, Spain,
were cultured in Ham’s F-12 medium supplemented with amino
acids and vitamins in the presence of 10% fetal bovine serum
(FBS) and antibiotics. For TGF-b treatments, human recombinant
TGF-b1 (R&D Systems GmbH, Germany) was used at 5 ng/ml.
For stable transfections, 106 cells seeded on 60 mm plates
were transfected with 5 lg of either antisense mouse-SKIP plasmid
or empty pCDNA3 vector using Superfect (Qiagen, Hilden, Ger-
many) following the manufacturer’s instructions. Transfected cells
were selected by growing in medium containing 10% FBS and
400 lg/ml of G418 for 2 weeks. Individual clones were isolated
by cloning rings.
Transient transfections to analyze PAI-1 promoter activity and
E2F-luc and CAGAC-luc transactivation were performed as previ-
ously described [12]. Fireﬂy luciferase activity (Promega, Adison
WI, USA) was standardized for b-galactosidase activity (Tropix,
Bedford, MA, USA).2.3. Immunoﬂuorescence and immunoblotting
E-cadherin, ﬁbronectin, vimentin, and ZO-1 were detected by
immunoﬂuorescence and Western blot assays as previously
described [13].2.4. RT-PCR
Two micrograms total RNA isolated from PDV/M and AS-S cells
was reverse transcribed with Superscript II (Invitrogen, Carlsbad,
CA). PCR products were obtained after 30–35 cycles of ampliﬁca-
tion with an annealing temperature of 55–60 C.
The primer sets used were as follows:
50-ATC-CTG-CCT-AAG-TTC-TCT-CTG-30,
50-ATT-GTC-TCT-GTC-GGG-TTG-TG-30, PAI-I (300 bp);
50-TGC-CCA-AGG-AAA-TTC-TGC-CCA-AGG-AAA-TTC-CAC-GC-30,
50-GCC-AAT-CTG-CAC-ATA-GCA-CC-30, uPA (280 bp);
50-TTC-CAC-CGA-ATG-GCT-TCC-AG-30,
50-AGG-CAA-TGA-GGC-TGA-GTT-GAG-C-30, uPAR (240 bp);
50-CGT-GAT-GAA-GGT-CTC-AGC-C-30
50-ATG-GGG-GCT-TCA-TTC-AC-30, m-E-cadherin (650 bp);
50-CCC-AGA-CTT-ATG-GTG-GCA-ATT-30,
50-AAT-TTC-CGC-CTC-GAG-TCT-GA-30, ﬁbronectin (220 bp);
50-CTG-GAG-AAG-AGC-TAC-GAA-CTG-30,
50-GGT-TGG-CAG-AGG-CAGA-GAA-AT-30, vimentin (790 bp);
50-GCA-GCT-GGC-CAG-GCT-CTC-GGT-GG-30
50-GTA-GCT-GGG-TCA-GCG-AGG-GCC-TCC-30, Snail (400 bp);
50-ACC-ACAG-TCC-ATG-CCA-TCA-C-30,
50-TCC-ACC-ACC-CTG-TTG-CTG-TA-30, GAPDH (480 bp).2.5. Migration, invasion and zymographic assays
The motility properties of cell transfectants were analyzed by
an in vitro wound healing assay. Wounded cell cultures were al-
lowed to grow for 24 h in the absence or presence of TGF-b1. The
capacity of the cells to invade Matrigel-coated ﬁlters was assayed
as described elsewhere [14]. Urokinase type plasminogen activator
(uPA) activity was assayed in a serum-free medium conditioned for
24 h in cell cultures treated or not with TGF-b1 subjected to SDS–
PAGE and casein-zymography, as reported [14].
2.6. Proliferation assay
5  103 cells were seeded in 96 well plates, and treated with
different amounts of TGF-b1 for 48 h. 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) at 0.5 mg/ml ﬁnal
concentration was added to each well, after 2 h the formazan crys-
tals were dissolved with DMSO:isopropanol (2:3) and the absor-
bance determined at 570 nm in a plate reader.
2.7. Statistics
Data are given as means ± S.D. from at least three independent
experiments. When necessary, statistical signiﬁcance was evalu-
ated using the Students’ t-test. Differences (*, &) were considered
to be signiﬁcant at a value of P < 0.005.
3. Results
3.1. Effect of TGF-b1 on SKIP expression in PDV cells and antisense SKIP
clones characterization
TGF-b1 treatment for different periods of time increased SKIP
expression in PDV cells, as determined by Western blot (Fig. 1A).
To elucidate whether SKIP has a role in the enhancement of cell
malignity by TGF-b1, PDV cells were stably transfected with a SKIP
antisense construction. Fig. 1B shows two clones with reduced
expression of SKIP, designated as AS-S, in comparison with control
PDV/Mock (PDV/M) cells. Having established that TGF-b1 enhances
SKIP expression, we further investigated whether SKIP depletion
modulates Smad3 signaling in PDV cells. Fig. 1C shows an inhibi-
tion and shorter duration of TGF-b1-induced Smad3 phosphoryla-
tion in AS-S cells compared with control cells. In addition, using the
speciﬁc Smad3 reporter, CAGAC-luc, we found that AS-S cells have
lower transcriptional activity of Smad3 after TGF-b1 treatment
compared with PDV/M control cells (Fig. 1D).
3.2. SKIP modulates TGF-b1-induced epithelial mesenchymal
transition of PDV cells
Chronic exposure of PDV cells to TGF-b1 induces cell scattering
during the ﬁrst week of treatment followed by a complete EMT
[15]. Therefore, we analyzed whether SKIP is required for TGF-
b1-induced EMT. Cells were treated with TGF-b1 for 3 days and
the changes related with EMT were assessed. As shown in
Fig. 2A, in PDV/M cells TGF-b1: induced delocalization/downregu-
lation of E-cadherin (E-Cad) (a and b) and ZO-1 (e and f); induced
deposition of ﬁbronectin (i and j); and enhanced the expression of
vimentin (m and n). Whereas in AS-S cells TGF-b1: disabled
delocalization of E-Cad (c and d) and ZO-1 (g and h); decreased
the expression of ﬁbronectin (k and l) and vimentin (o and p), as
determined by immunoﬂuorescence assays. These results, were
conﬁrmed by RT-PCR and Western blot analyses (Fig. 2B and C):
AS-S cells did not respond to TGF-b1 treatment, the expression of
E-cadherin, ﬁbronectin, and vimentin were not enhanced in com-
Fig. 1. TGF-b1 enhances SKIP expression in PDV cells. Antisense depletion of SKIP, and Smad3 signaling. (A) Expression of SKIP in PDV cells treated with TGF-b1 for different
time periods, determined by Western blot. a-Tubulin was used as a control of protein loading. (B) SKIP antisense depletion in PDV cells determined by Western blot: PDV
Mock (PDV/M) and antisense transfected cell clones (AS-S). (C) Smad3 phosphorylation in PDV/M and AS-S cells after of TGF-b1 treatment at times indicated, determined by
Western blot. (D) Transcriptional activity of Smad3 in PDV, PDV/M and AS-S cells detected through Smad3 speciﬁc CAGAC-luc reporter and determined as Smad3
transactivation after TGF-b1 treatment compared with the basal level.
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transcriptional repressor Snail, which has also been found to be in-
volved in EMT [16], was strongly inhibited in AS-S cells.
3.3. SKIP depletion sensitises PDV cells to the TGF-b1-induced
inhibition of cell proliferation and reduces cell migration and invasion
The downregulation of SKIP in PDV cells enhanced their sensi-
bility to low concentrations of TGF-b1 (0.1–1 ng/ml) which re-
sulted in stronger inhibition of proliferation. At relatively high
concentrations of TGF-b1 (more than 1 ng/ml) a similar inhibition
of proliferation was observed in both cell clones (Fig. 3A). Also, AS-
S cells in basal conditions proliferate slower than PDV/M control
cells (Fig. 3A, insert). Given that it was demonstrated that SKIP
can overcome the Rb inhibition of cell proliferation [11], we further
explored whether SKIP depletion modulates the activity of the cell
cycle regulator E2F, which in turn is regulated by Rb. As an exper-
imental approach a luciferase reporter construct containing re-
sponse elements to E2F was used. In the absence of TGF-b1, AS-S
cells showed lower E2F activity compared to control cells, and nodifference in TGF-b1-induced inhibition of E2F transactivation
was observed between AS-S and control cells (Fig. 3B).
Since EMT is associated with enhanced cell migration and inva-
siveness [1,2], it was further tested whether SKIP is necessary for
TGF-b1-induced cell motility, using a wound healing assay. While
untreated PDV/M cells were unable to close the wound area, the
TGF-b1-stimulated cells closed it completely. In contrast, TGF-
b1-stimulated cell motility was strongly inhibited in AS-S cells
(Fig. 3C). Finally, AS-S cells displayed reduced cell invasiveness
through the reconstituted basal membrane Matrigel after a
three-day treatment with TGF-b1 compared to PDV/M control cells
(Fig. 3D).
3.4. SKIP modulates uPA and PAI-1 expression
We have previously shown that TGF-b1 promotes the expres-
sion of uPA associated with the stimulation of invasive properties
in PDV cells [14]. In order to analyze whether SKIP is involved in
TGF-b1-induced uPA expression, the secretion of uPA activity in
the conditioned media of both cell clones was studied. As shown
Fig. 2. SKIP is required for TGF-b1-induced epithelial mesenchymal transition of PDV cells. (A) Immunoﬂuorescence analysis of E-cadherin, ZO-1, ﬁbronectin and vimentin in
the cell transfectants before and after stimulation (72 h) with TGF-b1. Note that TGF-b1 promotes a reduction of E-cadherin staining at cell-cell contacts (a, b) and ZO-1 (e, f);
increment in the expression of ﬁbronectin (i, j) and vimentin (m, n) in control cells, whereas expression of these proteins is opposite in AS-S cells (c, d; g, h; k, l; o, p, respectively).
(B) Expression of E-cadherin, ﬁbronectin, vimentin and Snail mRNA transcripts by RT-PCR in the cell transfectants before and after stimulation (48 h) with TGF-b1. GAPDHwas
ampliﬁed as a control for the amount of cDNA present in each sample. (C) Western blot analysis of E-cadherin, ﬁbronectin and vimentin expression in the cell transfectants. a-
Tubulin was used as a control of protein loading.
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inhibited in AS-S cells; this result paralleled that obtained by RT-
PCR analysis (Fig. 4B). Additionally, AS-S cells expressed less uPA
receptor after TGF-b1 treatment than control cells.
TGF-b1 is a potent inductor of plasminogen activator type-1 [1],
and the balance between PAI-1 and uPA regulates the capacity of
tumour cells to migrate and invade surrounding tissues [17]. As
shown in Fig. 4B, AS-S had an enhanced basal level of PAI-1 mRNA
production, which is slightly modiﬁed by TGF-b1, and reaches the
level of PAI-1 expression in control cells after TGF-b1 treatment.
Furthermore, a high transcriptional activity, near to that induced
by TGF-b1 in control cells, of the PAI-1 promoter (p800-luc) in
AS-S cells is observed in basal conditions, and was further
increased after TGF-b1 treatment.
4. Discussion
Given that TGF-b1 stimulates the epithelial mesenchymal tran-
sition (EMT) and invasiveness in tumoral cells [1,2], it is importantto discover which mechanisms control the intracellular signalling
of this factor in transformed cells. In addition, the SKIP has been
proven to modulate Smads’ activities in TGF-b1 signaling pathway
[6].
PDV cells originate from mouse skin chemical carcinogenesis
model, which upon subcutaneous injection produce well differen-
tiated epithelial tumours resembling squamous carcinoma grade II
[18]. The mouse skin chemical carcinogenesis model greatly con-
tributed in understanding cancer as a multi-stage tumour progres-
sion [18]. In vitro, PDV treatment with TGF-b1 triggers the EMT
[15], concomitantly with the enhancement of cell migration/inva-
sion and production of extracellular matrix degrading proteins
such as uPA and MMP-9 [13,14]. Considering these facts, PDV cells
represent a cellular tool convenient for the analysis of the molecu-
lar and biochemical mechanisms involved in TGF-b1-induced EMT
and tumour progression of epithelial cancer cells.
In the current study, we demonstrated that TGF-b1 increases
SKIP expression in transformed PDV keratinocytes, while SKIP
depletion in these cells, introduced by antisense strategy, de-
Fig. 3. SKIP downregulation enhances the TGF-b1-induced inhibition of cell proliferation and inhibits cell migration and invasion. (A) Cell proliferation determined by MTT
assay in PDV/M and AS-S cells after 48 h of TGF-b1 treatment and in basal conditions (insert). (B) Transcriptional activity of E2F in PDV/M and AS-S cells detected by E2F
speciﬁc reporter and determined through luciferase activity after TGF-b1 treatment (24 h) compared with the basal level. (C) Wound healing assay. Areas free of cells were
examined 24 h after wounding in the absence or presence of TGF-b1. Cells were ﬁxed and stained with crystal violet. (D) Cell invasion assay through Matrigel-coated ﬁlters.
The percentage of migrated cells was calculated in respect to the total number of viable cells at the end of the incubation period (3 days).
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are in agreement with previously reported by Leong et al. [6]; how-
ever, the role of SKIP in the TGF-b1-induced cell malignity was not
further explored by this group.
Depletion of SKIP in PDV cells produced an inhibition of TGF-
b1-induced EMT (Fig. 2). Even though the precise mechanism
which involves SKIP in the induction of EMT by TGF-b1 is un-
known, it is likely that it might be mediated through modulating
Smad3 activation, since Smad3 has been reported as a critical com-
ponent in the induction of EMT by TGF-b1 [19]. Our ﬁndings show
that AS-S cells neither downregulate the epithelial markers E-cad-
herin and ZO-1 nor increase the expression of mesenchymal mark-
ers, ﬁbronectin and vimentin, in response to TGF-b1. Also, the
expression of Snail, a Smad3-dependent immediate-early gene
and a potent repressor of E-cadherin expression during EMT
[16,20], was inhibited in AS-S cells impeding the downregulation
of E-cadherin by TGF-b1. Furthermore, the inhibition of Smad3 in
PDV cells disabled Snail induction by TGF-b1 (data not shown).
In the light of previous results showing that ﬁbronectin expression
is mediated by Smad3 [21], our results propose that SKIP might
cooperate with Smad3 in the induction of ﬁbronectin expression
by TGF-b1 in PDV cells. To complete EMT epithelial cells acquire
a mesenchymal cytoskeleton expressing vimentin [2], which is
dependent on Smad3 in cooperation with AP1 and Sp1 transcrip-
tion factors [22]. Low activation of Smad3 in AS-S cells hindered
cells to display the EMT in response to TGF-b1. Thus, these results
suggest that during TGF-b1-induced EMT an increment of SKIP is
necessary to consolidate the phenotypical changes, in part by
enhancing Smad3 signal transduction. Furthermore, it is known
that Smad3 / knockout mice are resistant to the induction ofskin chemical carcinogenesis [23], as well as that Smad3 largely
regulates EMT [18].
Moreover, TGF-b1 is a potent inhibitor of cell proliferation in
the early steps of tumor progression [1], and the augmentation of
SKIP expression could be responsible for cells’ resistance to the
inhibition of proliferation at low amounts of TGF-b1. SKIP has been
shown to release cells from G1 arrest induced by Rb (retinoblas-
toma protein) facilitating cell proliferation [10], whereas TGF-b1
maintains Rb hypophosphorylated during cell cycle arrest in early
G1 phase [24]. Results given here showing a slower cell prolifera-
tion of AS-S cells compared to PDV parental cells (Fig. 3A, insert),
are well correlated with a reduced E2F transactivity in SKIP de-
pleted cells in the absence of exogenous TGF-b1 (Fig. 3B). Since it
has been suggested that SKIP preferentially binds hypophosphory-
lated Rb [10], the reduced level of SKIP in AS-S may enhance the
Rb/E2F complex formation in basal conditions, resulting in lower
transactivation of E2F, as demonstrated by our results. Both AS-S
and control cells respond similarly to the inhibition of E2F transac-
tivity by TGF-b1 treatment (Fig. 3B), indirectly suggesting that in-
creased sensitivity to inhibition of cell proliferation by TGF-b1
observed in AS-S is independent of Rb/E2F complex induction by
the growth factor and that other cell cycle inhibitors (such as
p21) might be involved. It is necessary to perform further analyses
in order to determine the exact mechanism which implicates SKIP
in TGF-b1 effect on cell proliferation. SKIP perhaps counteracts the
effect of TGF-b1 changing the cell response to the growth factor.
This is an important point, since during tumour progression, cells
acquire resistance to the inhibition of proliferation by TGF-b1
[1,2] resulting in tumour growth, a process in which SKIP might
have a signiﬁcant role.
Fig. 4. SKIP depletion alters TGF-b1-induced urokinase type plasminogen activator
and Plasminogen activator inhibitor type-1 expression. (A) uPA activity was
determined by casein-plasminogen-zymography in the serum-free conditioned
media of cell transfectants untreated or treated with TGF-b1 for 48 h. The activity of
uPA produced a clear band in the gel by activating plasminogen. (B) Expression of
uPA, uPAR and PAI-1 mRNA transcripts by RT-PCR in the cell transfectants before
and after stimulation (24 h) with TGF-b1. GAPDH was ampliﬁed as a control for the
amount of cDNA present in each sample. (C) Transactivation of PAI-1 promoter in
PDV/M and AS-S cells. PAI-1 promoter activity was assayed in cells unstimulated
and stimulated with TGF-b1 for 48 h as luciferase inducible activity. b-Galactosi-
dase was used as an internal control of transfection. RLU, relative luciferase units.
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invasion capacity of cancer cells [1]. Our ﬁndings show that SKIP
expression is necessary for the cell migration and Matrigel invasion
induced by TGF-b1. The capacity of cell motility, in part, is related
with the expression of proteinase system which allows cells to de-
grade extracellular matrix [25]. We have previously reported that
TGF-b1 induces uPA in PDV cells [26], and the results presented
in this work introduce SKIP as a signiﬁcant factor for TGF-
b1-induction of uPA and its receptor (uPAR). Although it is not
yet established if SKIP modulates TGF-b1-induced uPA/uPAR
expression by downregulating Smad3, we are suggesting this as
one possibility regarding a recent work which reported Smad4 as
a mediator of uPA expression [27].
The activity of uPA is regulated by the expression of PAI-1 [28].
Surprisingly, downregulation of SKIP enhanced the production of
PAI-1 in contrast with the inhibition of Smad3 signaling. One con-
ceivable explanation could be the role of SKIP on retinoblastoma
inhibition. In hypophosphorylated state Rb is in complex with
E2F, a cell cycle regulator, whereas when Rb is phosphorylated
by CDKs E2F is released and in free form acts as an inhibitor ofPAI-1 expression [29]. Low expression of SKIP in AS-S cells may
keep Rb/E2F in complex, and decrease the transcriptional activity
of E2F as is observed in Fig. 3B, which could then result in an incre-
ment of PAI-1 expression independent of TGF-b1 stimulation. The
tuning of uPA/uPAR/PAI-1 balance is crucial for cell migration
and invasion [17], and SKIP appears to be a key factor for a feasible
expression of these proteins allowing efﬁcient migration. The
downregulation of SKIP produces an imbalance of this ratio in
inhibitory status of uPA system by enhancing PAI-1 and blocking
TGF-b1-induced uPA/uPAR.
SKIP downregulation is sufﬁcient to modify the cell’s response
to TGF-b1, which might be related with the alteration of Smad3
activation by the growth factor, and the modiﬁcation in cell signal
homeostasis changes the capacity of TGF-b1 to induce EMT and cell
migration. In addition, no signiﬁcant changes were found in TGF-
b1-induced ERK1,2 activation, a MAPK signalling involved in TGF-
b1-induced EMT [30] (data not shown). Due to the fact that TGF-
b1 uses a plethoric range of intracellular signaling pathways to en-
hance cell malignance, such as JNK, NFjD and Rho GTpases
[1,5,13], it remains to be resolved whether these pathways, beyond
Smad3, are affected by SKIP depletion in PDV cells, and if they also
may be involved in TGF-b1 -induced EMT and cell migration.
Although signals other than Smad3 may be altered by changes in
SKIP expression, our ﬁndings propose that SKIP is an essential fac-
tor for TGF-b1-induced cell malignance, which suggests SKIP as a
possible target for the tumour growth and cancer dissemination
control. Also, additional studies in other EMT cellular models as
well as in vivo may help in completing a general picture of the role
of SKIP in TGF-b1-induced EMT.
In conclusion, the data presented here show that SKIP is re-
quired for the induction of EMT and the enhancement of cell malig-
nance by TGF-b1 in PDV transformed cells.Conﬂicts of interest statement
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